DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR METRONIDAZOLE HYDROCHLORIDE
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
505(b)(2) Clinical Trials for Metronidazole Hydrochloride
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Formulation | NCT01559545 | A Safety, Tolerability and Pharmacokinetic Study of Two Formulations of Metronidazole Versus Immediate Release Metronidazole in Patient With C. Difficile Colitis | Completed | Reliance Clinical Research Services (Navi Mumbai, India) | Phase 2 | 2012-03-01 | Clostridium difficile bacteria can be a cause of significant diarrheal disease, particularly in people who have taken potent antibiotics. When C. difficile multiplies within the colon, it produces two toxins that cause inflammation and resultant abdominal pain, fever and diarrhea. Current treatment of mild to moderate disease is with immediate release metronidazole, an antibiotic that kills C. difficile. Dr. Reddy's Laboratories has developed a delayed release form of metronidazole to release just before the colon to increase the concentration of antibiotic in the colon to improve the effectiveness of metronidazole treatment and potentially to allow less whole body exposure to the antibiotic. This study will measure the amount of metronidazole in the blood and stool of patients with C. difficile associated diarrhea (CDAD) to confirm that the new formulations are releasing the antibiotic as designed, immediately before the colon. |
| New Formulation | NCT01559545 | A Safety, Tolerability and Pharmacokinetic Study of Two Formulations of Metronidazole Versus Immediate Release Metronidazole in Patient With C. Difficile Colitis | Completed | Dr. Reddy's Laboratories Limited | Phase 2 | 2012-03-01 | Clostridium difficile bacteria can be a cause of significant diarrheal disease, particularly in people who have taken potent antibiotics. When C. difficile multiplies within the colon, it produces two toxins that cause inflammation and resultant abdominal pain, fever and diarrhea. Current treatment of mild to moderate disease is with immediate release metronidazole, an antibiotic that kills C. difficile. Dr. Reddy's Laboratories has developed a delayed release form of metronidazole to release just before the colon to increase the concentration of antibiotic in the colon to improve the effectiveness of metronidazole treatment and potentially to allow less whole body exposure to the antibiotic. This study will measure the amount of metronidazole in the blood and stool of patients with C. difficile associated diarrhea (CDAD) to confirm that the new formulations are releasing the antibiotic as designed, immediately before the colon. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for Metronidazole Hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00002682 | Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach | Completed | National Cancer Institute (NCI) | Phase 2 | 1995-08-01 | RATIONALE: Antibiotic therapy and antacids are used to treat Helicobacter pylori infection of the stomach. These treatments may also have an effect on gastric MALT lymphoma of the stomach. PURPOSE: Phase II trial to study the effectiveness of antibiotic therapy with amoxicillin, clarithromycin, tetracycline, and metronidazole plus antacids in patients with MALT lymphoma of the stomach. |
| NCT00002682 | Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach | Completed | M.D. Anderson Cancer Center | Phase 2 | 1995-08-01 | RATIONALE: Antibiotic therapy and antacids are used to treat Helicobacter pylori infection of the stomach. These treatments may also have an effect on gastric MALT lymphoma of the stomach. PURPOSE: Phase II trial to study the effectiveness of antibiotic therapy with amoxicillin, clarithromycin, tetracycline, and metronidazole plus antacids in patients with MALT lymphoma of the stomach. |
| NCT00003151 | Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma | Completed | University of Glasgow | Phase 2 | 1997-09-01 | RATIONALE: Antibiotics may stop the growth of Helicobacter pylori which may be associated with gastric lymphoma. PURPOSE: Phase II trial to study the effectiveness of antibiotic therapy in treating patients with low grade gastric lymphoma that has not been previously treated. |
| NCT00003151 | Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma | Completed | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 | 1997-09-01 | RATIONALE: Antibiotics may stop the growth of Helicobacter pylori which may be associated with gastric lymphoma. PURPOSE: Phase II trial to study the effectiveness of antibiotic therapy in treating patients with low grade gastric lymphoma that has not been previously treated. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Metronidazole Hydrochloride
Clinical Trial Locations for Metronidazole Hydrochloride
Trials by Country
Clinical Trial Progress for Metronidazole Hydrochloride
Clinical Trial Phase
Clinical Trial Status
Clinical Trial Sponsors for Metronidazole Hydrochloride
Sponsor Name
| Sponsor Name for Metronidazole Hydrochloride | |
| Sponsor | Trials |
| National Taiwan University Hospital | 16 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 12 |
| Shanghai Jiao Tong University School of Medicine | 8 |
| [disabled in preview] | 6 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Export unavailable in trial.
Subscribe for complete access.
